PDS Biotechnology Corp. PDSB 深 滬
等待開盤 04-02 09:30:00 美东时间
0.6063
+0.001
+0.21%
華盛通- 最 高0.61
- 今 開0.60
- 成交量 12.84万股
- 最 低 0.575
- 昨 收 0.605
- 總市值 3384.10万
- 52周最高 1.915
- 市盈率 靜 --
- 換手率 0.23%
- 52周最低 0.5068
- 委 比 -99.35%
- 總股本 5581.57万
- 歷史最高 17.85
- 量 比 0.18
- 振 幅 5.79%
- 歷史最低 0.5068
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PDS Biotechnology Q4 EPS $(0.14) Beats $(0.20) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.20) by 30 percent. This is a 33.33 percent increase over losses of $(0.21) per share from
03-30 21:41
PDS Biotechnology Reports Early Positive Results In Cancer Study, Tweaks Late-Stage Cancer Trial To Speed Up Potential Approval
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business and
03-30 19:23
Earnings Scheduled For March 30, 2026
Companies Reporting Before The Bell • Liberty All Star Equity (NYSE:USA) is est...
03-30 19:11
PDS Biotechnology Corp Reported FY25 EPS Loss Of $0.74/Share, Cash Balance Of $26.7M
Full Year 2025 Financial ResultsNet loss for the year ended December 31, 2025, was approximately $34.5 million, or $0.74 per basic and diluted share, compared to a net loss of $37.6 million, or $1.03 per basic and
03-30 19:08
PDS Biotechnology Receives Nasdaq Noncompliance Notice, Gets Time Through Aug. 24 To Regain Compliance
https://www.sec.gov/ix?doc=/Archives/edgar/data/1472091/000114036126007478/ef20067044_8k.htm#fact-identifier-5
03-04 01:04
PDS Biotechnology Adopts Amended Protocol To Its Phase 3 VERSATILE-003 Clinical Study
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the adoption of a
02-20 21:36
PDS Biotechnology Announces U.S. Patent Office Issues Notice Of Allowance For Its PDS0101 Asset
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the U.S.
01-22 21:46
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MoonLake (NASDAQ:MLTX) stock rose 8.2% to $20.0 during Friday's after-...
01-10 05:05
PDS Biotechnology Submits Protocol Amendment To FDA For Its Phase 3 VERSATILE-003 Study
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company
01-09 21:47
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
2025-12-18 20:05
